Awareness of mutational artefacts in suboptimal DNA samples: possible risk for therapeutic choices

References

• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
   PubMed Web of Science ®Google Scholar
• Brastianos P, Carter S, Santagata S, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5(11):1164–1177.
   PubMed Web of Science ®Google Scholar
• Chen G, Mosier S, Gocke CD, et al. Cytosine deamination is a major cause of background noise in next generation sequencing. Mol Diagn Ther. 2014;18(5):587–593.
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Eng J Med. 2013;368(13):1199–1209.
   PubMed Web of Science ®Google Scholar
• De Mattos-Arruda L, Mayor R, Ng CK, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839.
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990.
   PubMed Web of Science ®Google Scholar
• Do H, Dobrovic A. Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase. Oncotarget. 2012;3(5):546–558.
   PubMed Web of Science ®Google Scholar
• Do H, Wong SQ, Li J, et al. Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. Clin Chem. 2013;59(9):1376–1383.
   PubMed Web of Science ®Google Scholar
• Dono M, Massucco C, Chiara S, et al. Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer. Mol Med. 2013;18:1519–1526.
   PubMed Web of Science ®Google Scholar
• Higgins MJ, Jelovac D, Barnathan E, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res. 2012;18(12):3462–3469.
   PubMed Web of Science ®Google Scholar
• Khoo BL, Grenci G, Jing T, et al. Liquid biopsy and therapeutic response: circulating tumor cell cultures for evaluation of anticancer treatment. Sci Adv. 2016;2(7):e1600274.
   PubMed Web of Science ®Google Scholar
• Kim S, Park C, Ji Y, et al. Deamination effects in formalin-fixed, paraffin-embedded tissue samples in the era of precision medicine. J Mol Diagn. 2017;19(1):137–146.
   PubMed Web of Science ®Google Scholar
• Kimura T, Okamoto K, Miyamoto H, et al. Clinical benefit of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy. Oncology. 2012;82(5):298–304.
   PubMed Web of Science ®Google Scholar
• Kockan C, Hach F, Sarrafi I, et al. SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA. Bioinformatics. 2017;33(1):26–34.
   PubMed Web of Science ®Google Scholar
• Lamy A, Blanchard F, Le Pessot F, et al. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Modern Pathol. 2011;24(8):1090–1100.
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P, Pekin D, Normand C, et al. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res. 2015;21(5):1087–1097.
   PubMed Web of Science ®Google Scholar
• Lindahl T. Instability and decay of the primary structure of DNA. Nature. 1993;362(6422):709–715.
   PubMed Web of Science ®Google Scholar
• Mancini I, Santucci C, Sestini R, et al. The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. J Mol Diagn. 2010;12(5):705–711.
   PubMed Web of Science ®Google Scholar
• Marchiò C, Mariani S, Bertero L, et al. Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. Neuro Oncol. 2017;19(3):451–453.
   PubMed Web of Science ®Google Scholar
• Mariani S, Di Bello C, Bonello L, et al. Flexible lab-tailored cut-offs for suitability of formalin-fixed tumor samples for diagnostic mutational analyses. PloSOne. 2015;10(4):e0121815.
   PubMed Web of Science ®Google Scholar
• Mariani S, Bertero L, Osella-Abate S, et al. Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene. Br J Cancer. 2017;117(3):358–366.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Favero F, de Bruin EC, et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med. 2015 Published Online First: 2015 April 15;7(283):283ra54.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and future. Cell. 2017;168(4):613–629.
   PubMed Web of Science ®Google Scholar
• Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532–536.
   PubMed Web of Science ®Google Scholar
• Molinari F, Felicioni L, Buscarino M, et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res. 2011;17(14):4901–4914.
   PubMed Web of Science ®Google Scholar
• Narayan A, Carriero NJ, Gettinger SN, et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res. 2012;72(14):3492–3498.
   PubMed Web of Science ®Google Scholar
• CAPRI-GOIM investigators, Normanno N, Rachiglio AM, Lambiase M, et al. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol. 2015;26(8):1710–1714.
   PubMed Web of Science ®Google Scholar
• Pääbo S, Irwin DM, Wilson AC. DNA damage promotes jumping between templates during enzymatic amplification. J Biol Chem. 1990;265(8):4718–4721.
   PubMed Web of Science ®Google Scholar
• Pérez-Báez W, García-Latorre EA, Maldonado-Martínez HA, et al. Impact of fixation artifacts and threshold selection on high resolution melting analysis for KRAS mutation screening. Mol Cell Probes. 2017;35:34–43.
   PubMed Web of Science ®Google Scholar
• Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403). DOI:10.1126/scitranslmed.aan2415
   PubMed Web of Science ®Google Scholar
• Pierce KE, Wangh LJ. Effectiveness and limitations of uracil-DNA glycosylases in sensitive real-time PCR assays. BioTechniques. 2004;36(1):44–46.
   PubMed Web of Science ®Google Scholar
• Senft D, Leiserson MDM, Ruppin E, et al. Precision oncology: the road ahead. Trends Mol Med. 2017;23(10):874–898.
   PubMed Web of Science ®Google Scholar
• Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531–548.
   PubMed Web of Science ®Google Scholar
• Stiller M, Green RE, Ronan M, et al. Patterns of nucleotide misincorporations during enzymatic amplification and direct large-scale sequencing of ancient DNA. Proc Natl Acad Sci USA. 2006;103(37):13578–13584.
   PubMed Web of Science ®Google Scholar
• Thierry AR, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20(4):430–435.
   PubMed Web of Science ®Google Scholar
• Tougeron D, Lecomte T, Pagès JC, et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2013;24(5):1267–1273.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lenz HJ, Köhne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33(7):692–700.
   PubMed Web of Science ®Google Scholar
• Venesio T, Siravegna G, Bardelli A, et al. Liquid biopsies for monitoring temporal genomic heterogeneity in breast and colon cancers. Pathobiology. 2017. Published Online First 2017 Jun 15. DOI:10.1159/000473882.
   PubMedGoogle Scholar
• Wei Q, Ye Z, Zhong X, et al. Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis. Annal Oncol. 2017;28(9):2135–2141.
   PubMed Web of Science ®Google Scholar
• Williams C, Pontén F, Moberg C, et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol. 1999;155:1467–1471.
   PubMed Web of Science ®Google Scholar
• Wong SQ, Li J, Tan AY, et al. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics. 2014;7:23.
   PubMed Web of Science ®Google Scholar